Apostolova, P., Kreutmair, S., Toffalori, C., Punta, M., Unger, S., Burk, A. C., . . . Zeiser, R. (2023). Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response. Web
Citación estilo ChicagoApostolova, Petya, et al. Phase II Trial of Hypomethylating Agent Combined With Nivolumab for Acute Myeloid Leukaemia Relapse After Allogeneic Haematopoietic Cell Transplantation—Immune Signature Correlates With Response. 2023.
Cita MLAApostolova, Petya, et al. Phase II Trial of Hypomethylating Agent Combined With Nivolumab for Acute Myeloid Leukaemia Relapse After Allogeneic Haematopoietic Cell Transplantation—Immune Signature Correlates With Response. 2023.